- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Oncoinvent ASA: Financial calendar | 1 | Oslo Børs | ||
| 13.12. | Oncoinvent lists on Euronext Growth Oslo | 2 | Euronext | ||
| 13.12. | Oncoinvent ASA: First day of trading on Euronext Growth Oslo and publication of information document | 2 | Oslo Børs | ||
| 12.12. | Oncoinvent ASA: Notifiable transactions in connection with Private Placement | - | Oslo Børs | ||
| 05.12. | Oncoinvent ASA announces oversubscribed private placement | 246 | PR Newswire | OSLO, Norway, Dec. 5, 2024 /PRNewswire/ -- Oncoinvent ASA ('Oncoinvent' or the 'Company') is pleased to announce that it has today successfully completed the bookbuilding process for a private... ► Artikel lesen | |
| ONCOINVENT Aktie jetzt für 0€ handeln | |||||
| 04.12. | Oncoinvent ASA: Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities | 191 | Business Wire | Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has entered into an agreement with ARTBIO, a clinical-stage radiopharmaceutical... ► Artikel lesen | |
| 11.11. | ONCOINVENT AS: Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses | 2 | Cision News | ||
| 11.11. | Oncoinvent ASA: Oncoinvent Announces Promising Interim Results for Radspherin as a Potential Treatment for Peritoneal Carcinomatoses | 284 | Business Wire | Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the... ► Artikel lesen | |
| 01.11. | Oncoinvent Announces Publication of 18-Month Safety and Efficacy Data from the Phase 1/2a Study of Radspherin in Colorectal Cancer | 279 | Business Wire | Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the publication of data from the Phase 1/2a study of Radspherin® in colorectal... ► Artikel lesen | |
| 28.10. | Oncoinvent AS: Oncoinvent to Present at JonesTrading Virtual Radiopharma Day | 196 | Business Wire | Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual panel discussion... ► Artikel lesen | |
| 10.10. | Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin in Ovarian Cancer Patients | 235 | Business Wire | U.S. Food and Drug Administration (FDA) recently granted Fast Track designation for Radspherin® for the treatment of patients with peritoneal metastases from ovarian cancer
Oncoinvent, a clinical... ► Artikel lesen | |
| 10.10. | ONCOINVENT AS: Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients | 1 | Cision News | ||
| 10.10. | Oncoinvent AS: Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin in Ovarian Cancer Patients | 228 | PR Newswire | OSLO, Norway, Oct. 10, 2024 /PRNewswire/ -- Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced that the first patient... ► Artikel lesen | |
| 28.08. | Oncoinvent ASA: Oncoinvent Appoints Oystein Soug as CEO | 272 | Business Wire | New CEO brings over 15 years of proven leadership experience, including deep expertise growing international radiopharmaceutical companies.
Oncoinvent ASA, a clinical stage radiopharmaceutical... ► Artikel lesen | |
| 25.06. | Oncoinvent's Radspherin has FDA fast-track status for ovarian cancer | 1 | Pharmaceutical Technology | ||
| 24.06. | Oncoinvent AS: Oncoinvent Receives FDA Fast Track Designation for Radspherin as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer | 214 | Business Wire | Phase 2b trial of Radspherin to treat ovarian cancer patients expected to initiate imminently
Oncoinvent AS, a clinical stage radiopharmaceutical company advancing alpha emitter therapy across... ► Artikel lesen | |
| 15.05. | Oncoinvent AS: Oncoinvent to Present at Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit | 150 | Business Wire | Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at... ► Artikel lesen | |
| 02.04. | Oncoinvent AS: Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board | 790 | Business Wire | Newly elected members of Board of Directors consist of internationally merited business and clinical leaders Formation of Scientific and Clinical Advisory Board leverages expertise of renowned... ► Artikel lesen | |
| 21.02. | Oncoinvent AS: Oncoinvent to Present at Evercore ISI 2024 Emerging Biotech Conference | 223 | Business Wire | Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will present at the Evercore ISI 2024 Emerging... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| QIAGEN | 42,900 | +0,04 % | Qiagen NV-Aktie läuft heute schlechter (42,62 €) | Im Minus liegt aktuell der Anteilsschein von Qiagen NV . Die Aktie kostete zuletzt 42,62 Euro. Am Aktienmarkt hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,62 Prozent verbilligt.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 8,405 | +1,08 % | Evotec-Aktie: Geht es jetzt weiter bergab - oder kommt doch noch in Kürze der große Durchbruch? Wir analysieren und verraten Ihnen unsere Tradingidee! | © Foto: SymbolbildWas passiert mit Evotec? Die Aktie des Hamburger Biotech-Unternehmens hatte 2024 kein einfaches Jahr: Fast 60 Prozent Kursverlust, Gerüchte über eine Übernahme und die Rückkehr in... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| HUMACYTE | 4,635 | +33,77 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
| JANUX THERAPEUTICS | 56,70 | -0,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 5,140 | +3,21 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| IMMUNOVANT | 25,880 | +0,86 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
ONCOINVENT ASA gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOINVENT ASA finden Sie auf Wallstreet Online.
